QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: mol.107.039826v1 72/6/1457    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okino, S. T. Articles by Dahiya, R. Search for Related Content PubMed PubMed Citation Articles by Okino, S. T. Articles by Dahiya, R.

A Dioxin-Responsive Enhancer 3' of the Human CYP1A2 Gene

Department of Urology, San Francisco Veterans Affairs Medical Center and the University of California San Francisco, San Francisco, California (S.T.O., D.P., R.D.); and Department of Medicine, School of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, Colorado (L.C.Q., M.I.)

The human CYP1A genes CYP1A1 and CYP1A2 are in a head-to-head orientation on chromosome 15. Both CYP1A genes and CYP1B1 are transcriptionally induced by the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that binds 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin). Although the TCDD-responsive enhancers for CYP1A1 and CYP1B1 are well characterized, a similar CYP1A2 enhancer has not been identified. In the human prostate cell line RWPE-1, CYP1A2 mRNA expression is dramatically induced by TCDD. Therefore, analysis of the native CYP1A2 gene in these cells can provide insight into its induction mechanism. To identify sites that may bind AhR on the CYP1A locus, we scanned 75 kilobases of chromosome 15 sequence for high-affinity AhR binding sites. We then analyzed most of the sites for TCDD-inducible AhR interaction by chromatin immunoprecipitation. As expected, the CYP1A1 and CYP1B1 enhancers bind AhR in TCDD-treated cells. It is noteworthy that we identify a region 3' of CYP1A2 that also binds AhR in response to TCDD. We cannot detect AhR binding at other sites on the CYP1A locus. In vivo footprinting demonstrates that two AhR binding sites in the CYP1A2 3' region are occupied in TCDD-treated cells. Reporter-gene studies show that these sites confer TCDD-responsiveness to a heterologous promoter. AhR also binds to the CYP1A2 3' region in TCDD-treated LS180 cells but not in HepG2 and ND-1 cells. In the latter cell lines, the CYP1A2 3' region is extensively methylated. In summary, we identify a novel TCDD-responsive enhancer for CYP1A2. We were surprised to find that this enhancer is not conserved across species and is primarily human-specific.

Address correspondence to: Dr. Rajvir Dahiya, Department of Urology, San Francisco Veterans Affairs Medical Center and UCSF, 4150 Clement Street, Building 203 room 2B-24 (112F). San Francisco, CA 94121. E-mail: rdahiya{at}urology.ucsf.edu

This article has been cited by other articles:

				R. F. Place, L.-C. Li, D. Pookot, E. J. Noonan, and R. Dahiya MicroRNA-373 induces expression of genes with complementary promoter sequences PNAS, February 5, 2008; 105(5): 1608 - 1613. [Abstract] [Full Text] [PDF]